UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003629
Receipt number R000004401
Scientific Title Phase II study of surgical resection following neoadjuvant chemoradiation using Gemcitibine and TS-1 in patients with potentially and borderline resectable pancreatic cancer
Date of disclosure of the study information 2010/06/01
Last modified on 2018/11/23 20:44:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of surgical resection following neoadjuvant chemoradiation using Gemcitibine and TS-1 in patients with potentially and borderline resectable pancreatic cancer

Acronym

Phase II study of surgical resection following neoadjuvant chemoradiation in pancreatic cancer

Scientific Title

Phase II study of surgical resection following neoadjuvant chemoradiation using Gemcitibine and TS-1 in patients with potentially and borderline resectable pancreatic cancer

Scientific Title:Acronym

Phase II study of surgical resection following neoadjuvant chemoradiation in pancreatic cancer

Region

Japan


Condition

Condition

potentially and borderline resectable pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

to examine the efficacy and safety

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

frequency of radical resection (R0)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

To investigate the frequency of histological curative resection following chemoradiation using Gemcitabine and TS-1in patients with potentially resectable pancreatic cancer

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1.Patients with Histo-cytologically confirmed pancreatic cancer
2.Patients who have not undergone chemo and/or radiotherapy
3.Patients with radiologically defined patentially resectable pancreatic cancer
4.Patients with no metastatic disease confirmed by staging laparoscopy
5.Patients with Performance status of 0/1
6.Patients with sustained organ function
7.Patients with potentially resectable pancreatic cancer by CT following neoadjuvant chemoradiation
8.Patients who received informed consent

Key exclusion criteria

1) Patients with other active cancers
2) Patients with watery diarrhea
3) Intractable pleural and pericardical effusion, or ascites
4) Severe co-morbid diseases
5) Pregnancy or insufficient contraception
6) Past history of severe drug-allergy
7) Active bacterial or viral infection
8) younger than 20 years old or older than 90 years old.
9) No written informed consent of the patients
10) Pregnancy or insufficient contraception
11) HIV infection
12) Doubtful understanding or contractual capacity of the patient
13) Patients seems inadequate for this study by investigator(s)

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sohei SATOI MD

Organization

Kansai Medical University Hospital

Division name

Department of Surgery

Zip code


Address

2-3-1, Shin-machi, Hirakata, Osaka 573-1191

TEL

072-804-0101

Email



Public contact

Name of contact person

1st name
Middle name
Last name Sohei SATOI MD

Organization

Kansai Medical University Hospita

Division name

Department of Surgery

Zip code


Address


TEL


Homepage URL


Email

satoi@hirakata.kmu.ac.jp


Sponsor or person

Institute

Kansai Medical University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2010 Year 05 Month 18 Day

Date of IRB


Anticipated trial start date

2010 Year 06 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 05 Month 18 Day

Last modified on

2018 Year 11 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004401


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name